LIGHT-Responsive HVEM/NF-κB Reporter Jurkat Cell Line
LIGHT-Responsive HVEM/NF-κB Reporter Jurkat Cell Line is a Jurkat cell line designed for monitoring HVEM (Herpes virus entry mediator) related NF-κB (nuclear factor κB) signal transduction pathways. It contains a firefly luciferase reporter driven by four copies of the NF-κB response element and expresses human HVEM. After activation by the HVEM ligand LIGHT, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter.
Figure 1: Mechanism of action of LIGHT-Responsive HVEM/NF-κB Jurkat Cell Line in response to LIGHT.
LIGHT, either as a soluble ligand or when present on the cell surface of a cell, binds to HVEM, and NF-ĸB transcription factors is activated, inducing transcription of the luciferase reporter.
Interested in screening and profiling inhibitors, blocking antibodies, or activators of HVEM without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
Name | Ordering Information |
Thaw Medium 2 | BPS Bioscience #60184 |
Growth Medium 2A | BPS Bioscience #60190 |
Materials Required for Cellular Assay
Name | Ordering Information |
Assay Medium: Thaw Medium 2 | BPS Bioscience #60184 |
LIGHT, His-Tag (Human) Recombinant | BPS Bioscience #71266 |
LIGHT-CHO Recombinant Cell Line | BPS Bioscience #79262 |
IKK-16 dihydrochloride: inhibitor of NF-κB activation | Sigma #SML1138 |
NF-κB Luciferase Reporter Jurkat Cell Line | BPS Bioscience #60651 |
96-well tissue culture-treated white clear-bottom assay plate | Corning #3610 |
ONE-Step™ luciferase assay system | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
HVEM (Herpes virus entry mediator), also known as CD270 or TNFRSF14, is a human cell surface receptor of the TNF-receptor superfamily that can act as both a co-stimulatory and a co-inhibitory receptor of T cells. Binding of HVEM to one of its ligands, LIGHT (CD258, TNFSF14) or LTα (lymphotoxin-α), causes a co-stimulatory signal which can activate lymphoid cells. Alternately, interaction with BTLA (CD272) or CD160 causes a co-inhibitory signal which negatively regulates T-cell immune responses. HVEM has also been shown to interact with the adaptor proteins TRAF2 and TRAF5 and is critical to herpes simplex virus (HSV) cellular entry. LIGHT, either in the soluble form or as oligomers expressed on the cell surface, can activate NF-κB signaling pathway through binding to HVEM. The LIGHT/HVEM axis are co-stimulatory immune checkpoint molecules extensively studied in cancer immunotherapy.
Chen L. and Flies D., 2013 Nat Rev Immunol. 13(4): 227–242.
Steinberg M., et.al. 2014 Immunol Rev. 244(1): 169–187.
Rio M., et.al. 2014 Transplantation. 15; 98(11): 1165–1174.
Shui W., et.al. 2014 Immune Netw. 14(2): 67–72.
Steinberg M., et.al. 2009 Semin. Immunopathol. 31: 207-221.
Ware C., 2009 Adv.Exp.Med.Biol. 647:146.